Search
fluticasone/umeclidinium/vilanterol (Trelegy Ellipta)
Indications:
- maintenance treatment of COPD with asthma or eosinophilia
- maintenance treatment of asthma
* no improvement in mortality [2]
* safe for patients with cardiovascular disease [2]
* predominantly benefits patients with elevated blood eosinophil count (> 300 x 10E6/L) [1]
Contraindications:
- not FDA-approved to treat asthma in children or adolescents or to treat acute bronchospasm [2]
Dosage:
- once a day dry powder
Laboratory:
- complete blood count
- eosinophil count: > 300 x 10E6/L [1]
Mechanism of action:
- combination of inhaled glucocorticoid (fluticasone) with long-acting beta-2 adrenergic receptor agonist (vilanterol) & muscarinic antagonist
General
LABA/LAMA glucocorticoid combination (triple therapy)
References
- Labaki WW, Rosenberg SR.
Chronic obstructive pulmonary disease.
Ann Intern Med 2020 Aug 4; 173:ITC17
PMID: 32745458
- Agusti A, Celli BR, Criner GJ et al.
Global Initiative for Chronic Obstructive Lung Disease 2023 Report:
GOLD executive summary.
Am J Respir Crit Care Med. 2023 Apr 1;207(7):819-837.
PMID: 36856433 PMCID: PMC10111975 Free PMC article
https://www.atsjournals.org/doi/10.1164/rccm.202301-0106PP
- Highlights of Prescribing Information
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilantero
https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF